News

Inhaled APN01, Potential PAH Therapy, Safe in Healthy Adults

An inhaled form of APN01 (alunacedase alfa), APEIRON Respiratory Therapies (AResT)’s investigational therapy for certain lung diseases, was safe and well-tolerated in healthy people, according to data from a Phase 1 clinical trial. “In addition to meeting all primary [goals] regarding the safety and tolerability of APN01 via a new…

Virginia Venture Partners Invests in OxiWear Device for PH

Virginia Venture Partners — Virginia Innovation Partnership Corporation (VIPC)’s equity investment program — is investing in OxiWear and its modern ear-wearable device that’s designed to continuously monitor blood oxygen levels in people with pulmonary hypertension (PH). The OxiWear device alerts the user through a phone app when there’s…

Remodulin Pre-treatment Allows Higher Orenitram Doses

A short treatment with Remodulin (injectable treprostinil) before initiating Orenitram (oral treprostinil) allows pulmonary arterial hypertension (PAH) patients to achieve double the normal doses of the oral therapy without increasing side effects. These are the findings of a preliminary analysis of top-line data from the Phase…

Interactive Calendar of Resources, More to Mark PH Awareness Month

Patients, caregivers, family members, and friends are set to mark Pulmonary Hypertension Awareness Month, observed each November to call attention to the complex, chronic, progressive disorder. Awareness and education are vital to heightening the recognition, diagnosis, understanding, and management of pulmonary hypertension (PH), a disease associated with high blood…

Study Ties anti-VEGF Therapies to PH in Preterm Newborns

Premature newborns who are treated for eye problems with anti-VEGF therapies may be at increased risk of developing pulmonary hypertension, a new study suggests. “Future studies evaluating the safety of anti-VEGF therapy should include pulmonary hypertension as a key clinical outcome. This is especially important as anti-VEGF treatment usage…

CorVista Device to Diagnose PH Gets FDA Breakthrough Designation

The U.S. Food and Drug Administration (FDA) granted breakthrough device designation to the CorVista System, a point-of-care diagnostic tool that aims to use non-invasive tests and machine learning to help diagnose pulmonary hypertension and other cardiovascular disorders. The designation gives CorVista Health, the system’s developer, certain benefits aimed…

Adcirca, Revatio May Improve Survival in PH Due to Lung Disease

Treatment with Adcirca (tadalafil) or Revatio (sildenafil) may help patients who develop pulmonary hypertension secondary to an interstitial lung disease to live longer, according to a new study from the U.K. “Patients treated with [these therapies] survived longer than untreated patients,” the researchers wrote, noting a median survival of…